阿托梅苏斯报告说,经过林业发展局2027年的核准,第3阶段的基因治疗治疗一种稀有基因紊乱的试验取得成功。 Atomesus reports successful Phase 3 trials for a gene therapy treating a rare genetic disorder, with FDA approval possible by 2027.

Atomesus是一家生物技术公司,于2026年2月23日宣布成功完成第三阶段临床试验,以针对一种罕见的遗传障碍进行实验性基因治疗。 Atomesus, a biotechnology company, announced on February 23, 2026, the successful completion of Phase 3 clinical trials for its experimental gene therapy treatment targeting a rare genetic disorder. 该疗法旨在纠正ALD1基因的特定突变,显示患者结果显著改善,没有严重不良事件报告。 The therapy, designed to correct a specific mutation in the ALD1 gene, showed significant improvement in patient outcomes with no serious adverse events reported. 该公司计划在今年晚些时候向FDA提交监管申请,预计到2027年可能获得批准和市场上投入使用. The company plans to submit a regulatory application to the FDA later this year, with potential approval and market availability expected by 2027.